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In vitro activity of CART33, compared to control untransduced T cells
T cell effector function CART33* UTD
% Degranulation (4 hr incubation with MOLM14) 98% 1.3%
% Speciﬁc Lysis (E:T 0.625:1) 65.7% 30%
CFSE based proliferation (5-day incubation
with MOLM14)
91.6% 3%
Cytokine production, 24-hour incubation
with MOLM14 (median, pg/mL)
IL6 22.65 5.73
GM-CSF 13248 16.9
MIP-1b 8180 9.15
INF-g 24989 0.35
IL-2 9300 0.39
*All p values <0.05 when compared to UTD.
Figure 2. The combination of RNA-CART33 and chemotherapy result in
deeper and prolonged response of leukemia in M0LM14 engrafted xenografts.
NSG mice were injected with MOLM14-luc(lxl0(6) I.V) and imaged to
conﬁrmed engraftment four days later. Mice were then randomized to receive
either RNA-CART33 with cyclophosphamide or untransduced T cells with
cyclophosphamide (60 mg/kg L.P). T cell were given at a dose if 10x10(6) I.V in
three different doses, on days 5,9,16. Cyclophosphamide was given on days 8
and 14.1
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Allogeneic stem cell transplantation (allo-SCT) is the only
potentially curative option in relapsed or high risk acute
myeloid leukemia (AML). However, patients are often
excluded due to refractory disease. Chimeric Antigen Re-
ceptor (CAR) T cell therapy has shown signiﬁcant efﬁcacy in
acute lymphoid leukemia and its successful translation to
AML would constitute a vertical advance in the ﬁeld.
CD33 is known to be expressed on AML blasts. We
developed a 2nd generation CAR from the anti-CD33 scFv of
Gemtuzumab ozogamicin, 41BB costimulation, CD3z
signaling domain, and a lentiviral (LV) vector. T cells were
transduced with this construct and expanded in culture us-
ing anti CD3/CD28 magnetic beads (CART33 cells).
In vitro, CART33 cells resulted in robust functions when
incubated with the CD33+ cell line MOLM14 (Table 1). In
NSG-S mice (NOD-SCID-gc-/- (NSG), additionally transgenic
for human stem cell factor, IL3 and GM-CSF) engrafted with
primary AML blasts, CART33 treatment eradicated AML
within 4 weeks and led to a long term disease free survival
(Figure 1).
CD33 is also expressed on normal myeloid progenitors.
Therefore, treatment with CART33 can potentially result in
myelotoxicity.We assessed the potential formyeloablation of
CART33 in humanized immune system (HIS) mice (NSGmice
engrafted with human fetal liver CD34+ cells). These mice
were treated with CART33 cells or control T cells. CART33
treatment resulted in human lineage cytopenias and in a
signiﬁcant reduction of CD34+CD38- hematopoietic stem
cells and CD34+CD38+ myeloid progenitors in the marrow.
Both the anti-leukemic activity and myeloablative po-
tential of CART33 could be used as a novel cellularFigure 1. Leukemic burden and overall survival in primary AML xenografts following
were injected on day 15 (1x105).conditioning regimen in refractory AML. However, the effect
of the CAR T cells would have to be terminated prior to
infusion of donor stem cells in order to avoid engraftment
failure. We therefore designed a transiently expressed
“biodegradable” mRNA modiﬁed CAR based on CART33. T
cells were electroporated with this construct and expressed
CAR for up to six days. When compared with LV transduced
CART33, RNA-modiﬁed CART33 cells resulted in comparable
in vitro effector functions that declined over time posttreatment with T cells. Primary AML was injected on Day 0 (5xl06) and T cells
Abstracts / Biol Blood Marrow Transplant 21 (2015) S25eS29S26electroporation, a desirable property in the setting of the
myeloablative potential that was seen in the LV-CART33. We
then tested the activity of RNA-CART33 in combination with
chemotherapy against leukemia in AML xenografts. NSG
mice were engrafted with MOLM14 and treated either with
cyclophosphamide plus RNA-CART33 or with cyclophos-
phamide plus control T cells. The combination of RNA-
CART33 and chemotherapy resulted in deeper and longer
leukemic response (Figure 2).
In conclusion, our preclinical studies show potent activity
CART33 against AML. Biodegradable CART33 could poten-
tially be used as a novel anti-leukemic cellular conditioning
regimen in patients with relapsed AML without rejection of
the donor graft.Figure 2. Numbers of Oocytes.
Figure 3. Numbers of Newborns.2
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Introduction: Infertility associated with ovarian failure is a
serious late complication for female survivors of allogeneic
hematopoietic stem cell transplantation (allo-SCT). While
the role of pretransplant conditioning regimen has beenwell
appreciated, it remains to be elucidatedwhether GVHD could
impact female fertility. We have addressed this issue in
murine models of allogeneic SCT.
Methods: Female B6D2F1 (H-2b/d) mice, remained uncon-
ditioned or conditioned with 12mg/kg busulfan and 120mg/
kg cyclophosphamide on day -7, were injected with 80 x 106
splenocytes from allogeneic B6 (H-2b) or syngeneic B6D2F1
donors on day 0. In the indicated experiments, 10 mg/kg
prednisolone (PSL) was administered daily from day 0 to 14
post SCT and every 3 days thereafter. The oocytes were
enumerated after stimulation with pregnant mare’s serum
gonadotropin (PMSG) and human chorionic gonadotropin
(hCG). The serum levels of anti-Müllerian hormone (AMH)
were measured to evaluate functions of granulosa cells.
Fertility was directly evaluated by mating recipient miceFigure 1. Serum levels of AMH on day21.with naive B6D2F1 males 5-6 times between day 14 and day
136.
Results: After unconditioned SCT, histological evaluation of
the ovaries from allogeneic recipients demonstrated donor T-
cell inﬁltration in the granulosa layers of follicles and
apoptosis of granulosa cells surrounded by lymphocytes,
whereas there was neither of these changes in syngeneic
animals. Serum levels of AMH, which is produced by gran-
ulosa cells and regulates ovarian follicle development, were
signiﬁcantly decreased in allogeneic animals compared to
syngeneic controls (Fig. 1). Upon superovulation, the
numbers of oocytes recovered from allogeneic animals
were signiﬁcantly less than those from syngeneic animals,
indicating an impairment of ovarian functions (Fig. 2).
Remarkably, allogeneic animals delivered signiﬁcantly less
numbers of newborns by day 136 after SCT than syngeneic
animals (Fig. 3). Next, we addressed whether GVHD
impacts on the ovary functions in non-myeloablative SCT
conditioned with busulfan and cyclophosphamide. Again,
there were histological evidences of donor T cell inﬁltration
and granulosa cell apoptosis, reduced oocytes, and
impaired fertility in allogeneic mice when compared to
